Suggested remit: To appraise the clinical and cost effectiveness of givinostat within its marketing authorisation for treating Duchenne muscular dystrophy in people 6 years and over. Anticipate the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback